Eli Lilly and Company $LLY Stock Sold by Sound Income Strategies LLC

Sound Income Strategies LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 62.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,209 shares of the company’s stock after selling 3,613 shares during the period. Sound Income Strategies LLC’s holdings in Eli Lilly and Company were worth $2,583,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Balefire LLC raised its stake in shares of Eli Lilly and Company by 3.2% during the third quarter. Balefire LLC now owns 4,398 shares of the company’s stock worth $5,089,000 after acquiring an additional 136 shares in the last quarter. Decker Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Decker Wealth Management LLC now owns 16,906 shares of the company’s stock worth $19,561,000 after acquiring an additional 113 shares during the last quarter. David J Yvars Group boosted its stake in shares of Eli Lilly and Company by 1.1% in the 3rd quarter. David J Yvars Group now owns 903 shares of the company’s stock valued at $1,045,000 after purchasing an additional 10 shares in the last quarter. Bullock Wealth Management Group grew its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Bullock Wealth Management Group now owns 2,983 shares of the company’s stock valued at $3,430,000 after purchasing an additional 21 shares during the last quarter. Finally, Avaii Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 51.5% during the 3rd quarter. Avaii Wealth Management LLC now owns 2,522 shares of the company’s stock valued at $2,883,000 after purchasing an additional 857 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound produced broader biological effects than Taltz alone in adults with psoriasis and obesity. By Week 36, the combination changed 482 proteins versus 140 with Taltz alone and affected 467 genes versus 16, alongside improved skin clearance and weight loss. The findings could strengthen Lilly’s case for treating interconnected metabolic and inflammatory conditions. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Analyst Cantor Fitzgerald raised its Eli Lilly price target to $1,440 from $1,410 and maintained an Overweight rating, implying meaningful upside based on continued obesity-drug demand and pipeline execution. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Recent coverage continues to highlight strong Zepbound demand, potential retatrutide and Foundayo catalysts, and expansion in oncology and Alzheimer’s research. Lilly’s second-quarter revenue growth of roughly 48% and raised outlook provide fundamental support for the long-term growth narrative.
• Neutral Sentiment: Despite its growth profile, Lilly trades below its historical average forward earnings multiple. That may indicate a valuation opportunity, but it also reflects investor concerns about competition, pricing pressure and whether the company’s exceptional growth can continue.
• Neutral Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative may improve future research productivity, although it is unlikely to materially affect near-term earnings. Nvidia and Eli Lilly AI drug-discovery lab
• Negative Sentiment: Lilly’s largest shareholder filed to sell approximately $347 million of stock. The transaction may be routine portfolio management, but its size can raise concerns about insider or major-holder confidence and create additional supply.
• Negative Sentiment: The company is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. Litigation creates regulatory, legal and reputational risk, although the financial impact remains uncertain.

Eli Lilly and Company Stock Up 0.7%

NYSE LLY opened at $1,177.57 on Friday. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The business’s 50-day moving average is $1,174.35 and its 200 day moving average is $1,097.02. The stock has a market capitalization of $1.11 trillion, a PE ratio of 39.52, a PEG ratio of 1.44 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 36.64 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on LLY shares. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. Leerink Partners increased their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Citigroup raised their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,313.43.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.